* Kinnate Biopharma Inc is expected to show no change in quarterly revenue when it reports results on March 13 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Kinnate Biopharma Inc is for a loss of 44 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50, below its last closing price of $2.58.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.67 -0.67 -0.65 Beat 3.7
Jun. 30 2023 -0.78 -0.75 -0.68 Beat 9.3
Mar. 31 2023 -0.70 -0.73 -0.73 Met 0
Dec. 31 2022 -0.72 -0.72 Met -0.6
Sep. -0.60 -0.61 -0.70 Missed -15.2
30 2022
Jun. 30 2022 -0.66 -0.64 -0.62 Beat 2.9
Mar. 31 2022 -0.62 -0.61 -0.61 Met -0.5
Dec. 31 2021 -0.60 -0.59 -0.60 Missed -2.2
This summary was machine generated March 11 at 20:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments